Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases

被引：7

作者：

Brandsma, D

Taphoorn, MJB

de Jager, W

Bonfrer, H

Algra, A

Reijneveld, JC

Boogerd, W

Korse, T

Verbeek, MM

Rijkers, GT

Voest, EE

机构：

[1] Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands

[2] Univ Utrecht, Med Ctr, Lab Med Oncol, Utrecht, Netherlands

[3] Univ Utrecht, Med Ctr, Dept Med Oncol, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Clin Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands

[5] Med Ctr Haaglanden, Dept Neurol, The Hague, Netherlands

[6] Univ Utrecht, Ctr Med, Wilhelminas Childrens Hosp, Utrecht, Netherlands

[7] Univ Utrecht, Ctr Med, Dept Pediat, Utrecht, Netherlands

[8] IACOPO Inst Translat Med, Utrecht, Netherlands

[9] Antoni Van Leeuwenhoek Hosp, Dept Clin Chem, Amsterdam, Netherlands

[10] Antoni Van Leeuwenhoek Hosp, Dept Neurol, Amsterdam, Netherlands

[11] Univ Nijmegen, Ctr Med, Dept Neurol, Nijmegen, Netherlands

来源：

NEUROLOGY | 2006年 / 66卷 / 02期

关键词：

D O I：

10.1212/01.wnl.0000194239.74384.57

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Median survival of patients with leptomeningeal metastases (LM) is 4 to 6 months, with a few long-term survivors. Current prognostic factors for survival have limited value. The authors measured the CSF levels of nine inflammatory proteins in 57 patients with LM and determined their prognostic value. High interleukin (IL)-8 CSF levels predicted short-term survival independently. The data indicate that IL-8 CSF levels may serve as a prognosticator in patients with LM, but prospective validation is needed.

引用

页码：243 / 246

页数：4